These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 16493614)

  • 1. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
    Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
    Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
    Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
    Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
    Kröger N; Zabelina T; Renges H; Krüger W; Kordes U; Rischewski J; Schrum J; Horstmann M; Ayuk F; Erttmann R; Kabisch H; Zander AR
    Ann Hematol; 2002 Nov; 81(11):627-31. PubMed ID: 12454700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
    Koh LP; Koh MB; Ng HY; Hwang WY; Goh YT; Linn YC; Ng HJ; Chuah CT; Tan KW; Loh YS; Tan DC; Tan PH; Tan PH
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):887-90. PubMed ID: 16864060
    [No Abstract]   [Full Text] [Related]  

  • 10. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation for severe aplastic anemia: graft rejection remains a problem.
    Aki SZ; Sucak GT; Ozkurt ZN; Yeğin ZA; Yağci M; Haznedar R
    Transfus Apher Sci; 2009 Feb; 40(1):5-11. PubMed ID: 19121979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-intensity conditioning for severe aplasia using fludarabine and CY followed by infusion of ex vivo T-cell-depleted grafts leads to excellent engraftment and absence of GVHD.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Bone Marrow Transplant; 2009 May; 43(10):779-85. PubMed ID: 19079315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.
    Bacigalupo A; Locatelli F; Lanino E; Marsh J; Socié G; Maury S; Prete A; Locasciulli A; Cesaro S; Passweg J;
    Bone Marrow Transplant; 2005 Dec; 36(11):947-50. PubMed ID: 16205733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
    Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
    Wu B; Guo K; Song Z; Yan D; Yang Y; Xiao L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):194-7. PubMed ID: 12133456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution.
    de la Rubia J; Cantero S; Sanz GF; Remigia MJ; Monteagudo E; Moscardó F; Martín G; Lorenzo I; Jiménez C; Martínez J; Montesinos P; Jarque I; Sanz MA
    Bone Marrow Transplant; 2005 Aug; 36(4):325-9. PubMed ID: 15968276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.